



## Endo Begins Shipment of Authorized Generic Version of INVANZ® (ertapenem for injection) in the United States

July 27, 2018

DUBLIN, July 27, 2018 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) announced today that one of its operating companies, Par Pharmaceutical (Par), has begun shipping an authorized generic version of Merck's INVANZ® (ertapenem for injection). Endo's subsidiary, Endo Ventures Limited, recently entered into an exclusive U.S. supply and distribution agreement with a subsidiary of Merck & Co., Inc., of Kenilworth, N.J. allowing Par to launch and distribute an authorized generic of the product.

According to IQVIA data, U.S. sales of INVANZ® were approximately \$390 million for the 12 months ending May 31, 2018.

INVANZ® is a registered trademark of Merck Sharp & Dohme Corp.

### **About Endo International plc**

Endo International plc (NASDAQ: ENDP) is a highly focused generics and specialty branded pharmaceutical company delivering quality medicines to patients in need through excellence in development, manufacturing and commercialization. Endo has global headquarters in Dublin, Ireland, and U.S. headquarters in Malvern, PA. Learn more at [www.endo.com](http://www.endo.com).

### **About Par Pharmaceutical**

Par Pharmaceutical, headquartered in Chestnut Ridge, NY, develops, manufactures and markets safe, innovative and cost-effective generic pharmaceutical products that help improve patient quality of life. Par, among the top leaders in the U.S. generics industry, possesses a portfolio that includes sterile injectables, alternative dosage forms and many other differentiated products. Par is advancing a research and development (R&D) pipeline of approximately 200 potential new products. Par is an operating company of Endo International plc. Learn more at [www.endo.com](http://www.endo.com) or [www.parpharm.com](http://www.parpharm.com).

### **Cautionary Note Regarding Forward-Looking Statements**

Certain information in this press release contains certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and any applicable Canadian securities legislation. Statements including words such as "believes," "expects," "anticipates," "intends," "estimates," "plan," "will," "may," "look forward," "intend," "guidance," "future" or similar expressions are forward-looking statements. Because these statements reflect our current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties. Investors should note that many factors, as more fully described under the caption "Risk Factors" in Endo's Form 10-K, Form 10-Q and Form 8-K filings with the Securities and Exchange Commission and in Canada on the System for Electronic Data Analysis and Retrieval and as otherwise enumerated herein or therein, could individually or in the aggregate affect Endo's future financial results and could cause Endo's actual results to differ materially from those expressed in the forward-looking statements or from historical results. The forward-looking statements in this press release are qualified by these risk factors. Endo assumes no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise, except as may be required under applicable securities laws.

 View original content: <http://www.prnewswire.com/news-releases/endo-begins-shipment-of-authorized-generic-version-of-invanz-ertapenem-for-injection-in-the-united-states-300687528.html>

SOURCE Endo International plc

Endo International plc: Media: Heather Zoumas-Lubeski, (484) 216-6829; Investors: Nina Goworek, (484) 216-6657